五脏阴阳整体论对痹证发生的机理研究—关节痹证与肺痹发生的临床与实验研究
摘要
中医藏象学说是中医学理论体系的核心组成部分,认为五脏是一个有机联系的整体,每一脏、每一腑虽然都有各自的生理功能,但它们在生理上会相互影响,在病理上相互传变。类风湿关节炎属于中医痹证的范畴,该证由于邪气壅塞,气血凝滞,容易传变于脏,预后不佳。我们从五脏整体观念出发,探讨关节痹证传变肺痹的相关性,并探讨肾虚在关节痹证发生相关肺损害的作用机理,为关节痹证发生肺损害的发生机制提供分子生物学依据,为提高临床疗效做好铺垫。1.目的
通过对五脏阴阳整体论思想的文献整理,以及类风湿关节炎合并间质性肺病的临床观察,结合实验研究,讨论类风湿关节炎发生肺损害的相关机理及肾虚对该病的影响,对指导临床用药有重要的指导意义。
2.方法
2.1理论研究采用文献学、逻辑分析等方法,对中医“五脏整体论”的内涵进行探讨分析,探讨关节痹证及肺痹发生的相关性,并探讨肾虚在关节痹证发生相关肺损害的影响。
2.2实验研究
2.2.1随机选取16只雌性SD大鼠,用注射CIA的方法造成痹证模型,观察关节痹证模型大鼠肺组织的病理改变,计算肺系数,分析肺组织上IL-1、IL-6、TNF-α、TGF-β的含量变化。
2.2.2随机选取64只SD大鼠,雌、雄各半,造成关节痹证模型、肾虚痹证模型、伪手术组模型、生理组模型,观察各组大鼠前腕关节肿胀情况,计算胸腺指数,检测、分析各组大鼠肺组织上IL-1、IL-6、TNF-α、TGF-β的含量变化。
3结果
3.1关节痹证对肺组织IL-1、IL-6、TNF-α、TGF-β的影响
3.1.1关节痹证模型组大鼠出现肺部的病理改变,且与生理组相比,关节痹证模型组大鼠肺系数比生理组高,P<0.05,具有统计学意义。
3.1.2与生理组相比,关节痹证模型组大鼠肺组织上IL-1、IL-6、TNF-α、TGF-β均显著升高,具有统计学意义,P<0.05。
3.2肾虚对关节痹证发生肺损害的影响
3.2.1雌性大鼠比雄性大鼠的发病率高。肾虚痹证比单纯关节痹证、伪手术组的发病率高。
3.2.2无论雌性还是雄性大鼠,与生理组相比,关节痹证组、肾虚痹证组、伪手术组胸腺指数降低,P<0.05,具有统计学意义,肾虚痹证的胸腺指数最低。
3.2.3无论雄性还是雌性大鼠,与生理组相比,关节痹证组、肾虚痹证组、伪手术组大鼠的肺组织上IL-1、IL-6、TNF-α、TGF-β均显著升高,具有统计学意义,P<0.05。肾虚痹证模型上的细胞因子升高得更为显著。
4结论
4.1关节痹证导致肺组织损伤,且IL-1、IL-6、TNF-α、TGF-β在肺损伤的过程中发挥重要作用。
4.2肾虚对关节痹证发生肺损害有相关性,肾虚可能会加重关节痹证及发生关节痹证继发性肺损伤。
The core of theoretical system of TCM is "visceral manifestation theory".It think that the five visceral is an organic whole, their physical interaction with each other in the pathological mass change although they have their own physiological functions. Rheumatoid arthritis belongs to the scope of "arthralgia" in TCM. The disease is easy to mass change, and very difficult to cure. Our departure from the concept of the five internal organs as a whole, To explore joint Arthralgia mass change related to lung paralysis. and to explore the kidney in the mechanism of joint Arthralgia related lung damage.Which will offord mechanism of molecular biology basis for joint Arthralgia lung damage, and pave the way to improve clinical outcomes.
1 Purpose
Sorting through the literature on the holism thinking of the five organs of yin and yang, And rheumatoid arthritis with interstitial lung disease, clinical observations, experimental research, Discuss rheumatoid arthritis occur related mechanism of lung damage and kidney disease, Significance in guiding clinical treatment.
2 Methods
2.1 Theoretical Study Use philology, logic analysis ways, Discuss analysis of the connotation of TCM "holism" of the five internal organs, Explore joint Arthralgia and pulmonary paralysis occurred, and to explore the kidney in joint Arthralgia related lung damage.
2.2 Experimental study
2.2.1 We selected 16 female SD rats Randomly, and then causing arthralgia model with Inject of CIA.Observed the pathological changes of the of arthralgia model of lung tissue, calculated the lung coefficient, analysised content of IL-1, IL-6, TNF-alpha and TGF-P of lung tissue.
2.2.2 We selected 64 SD rats randomly, male and female half. Made the arthralgia model, kidney arthralgia model, pseudo-operation group model. Calculated the index of thymus. Analysised content of IL-1, IL-6, TNF-alpha and TGF-βof lung tissue.
3 Result
3.1 The effect of arthralgia pass to lung
3.1.1 Arthralgia model group rats had lung pathological changes. And compared with the physiological group, lung coefficient is higher than the physical group, statistically significant(P<0.05).
3.1.2 Compared with the physiological group, the content of IL-1, IL-6, TNF-alpha, TGF-beta significantly increased in lung, statistically significant(P<0.05).
3.2 The role of renal in pathogenesis
3.2.1 High incidence of female rats than male rats. High incidence of kidney arthralgia than simply arthralgia, sham group.
3.2.2 Whether female or male rats, compared with the physiological group, the thymus index in arthralgia group, kidney arthralgia group, the sham group are lower (P<0.05), with statistical significance. Thymus index was the lowest in kidney arthralgia group.
3.2.3 Whether female or male rats, compared with the physiological group, the content of IL-1, IL-6, TNF-alpha, TGF-beta in arthralgia group, kidney arthralgia group, the sham group are higher (P<0.05), with statistical significance. The content in kidney arthralgia group are highest.
4 Conclusion
4.1 The arthralgia can cause lung tissue damage, IL-1, IL-6, TNF-alpha and TGF-beta in the process of lung injury play an important role.
4.2 Kidney related lung damage occurs to the joint Arthralgia, Kidney dificiency will increase arthralgia, and arthralgia secondary lung injury.
通过对五脏阴阳整体论思想的文献整理,以及类风湿关节炎合并间质性肺病的临床观察,结合实验研究,讨论类风湿关节炎发生肺损害的相关机理及肾虚对该病的影响,对指导临床用药有重要的指导意义。
2.方法
2.1理论研究采用文献学、逻辑分析等方法,对中医“五脏整体论”的内涵进行探讨分析,探讨关节痹证及肺痹发生的相关性,并探讨肾虚在关节痹证发生相关肺损害的影响。
2.2实验研究
2.2.1随机选取16只雌性SD大鼠,用注射CIA的方法造成痹证模型,观察关节痹证模型大鼠肺组织的病理改变,计算肺系数,分析肺组织上IL-1、IL-6、TNF-α、TGF-β的含量变化。
2.2.2随机选取64只SD大鼠,雌、雄各半,造成关节痹证模型、肾虚痹证模型、伪手术组模型、生理组模型,观察各组大鼠前腕关节肿胀情况,计算胸腺指数,检测、分析各组大鼠肺组织上IL-1、IL-6、TNF-α、TGF-β的含量变化。
3结果
3.1关节痹证对肺组织IL-1、IL-6、TNF-α、TGF-β的影响
3.1.1关节痹证模型组大鼠出现肺部的病理改变,且与生理组相比,关节痹证模型组大鼠肺系数比生理组高,P<0.05,具有统计学意义。
3.1.2与生理组相比,关节痹证模型组大鼠肺组织上IL-1、IL-6、TNF-α、TGF-β均显著升高,具有统计学意义,P<0.05。
3.2肾虚对关节痹证发生肺损害的影响
3.2.1雌性大鼠比雄性大鼠的发病率高。肾虚痹证比单纯关节痹证、伪手术组的发病率高。
3.2.2无论雌性还是雄性大鼠,与生理组相比,关节痹证组、肾虚痹证组、伪手术组胸腺指数降低,P<0.05,具有统计学意义,肾虚痹证的胸腺指数最低。
3.2.3无论雄性还是雌性大鼠,与生理组相比,关节痹证组、肾虚痹证组、伪手术组大鼠的肺组织上IL-1、IL-6、TNF-α、TGF-β均显著升高,具有统计学意义,P<0.05。肾虚痹证模型上的细胞因子升高得更为显著。
4结论
4.1关节痹证导致肺组织损伤,且IL-1、IL-6、TNF-α、TGF-β在肺损伤的过程中发挥重要作用。
4.2肾虚对关节痹证发生肺损害有相关性,肾虚可能会加重关节痹证及发生关节痹证继发性肺损伤。
The core of theoretical system of TCM is "visceral manifestation theory".It think that the five visceral is an organic whole, their physical interaction with each other in the pathological mass change although they have their own physiological functions. Rheumatoid arthritis belongs to the scope of "arthralgia" in TCM. The disease is easy to mass change, and very difficult to cure. Our departure from the concept of the five internal organs as a whole, To explore joint Arthralgia mass change related to lung paralysis. and to explore the kidney in the mechanism of joint Arthralgia related lung damage.Which will offord mechanism of molecular biology basis for joint Arthralgia lung damage, and pave the way to improve clinical outcomes.
1 Purpose
Sorting through the literature on the holism thinking of the five organs of yin and yang, And rheumatoid arthritis with interstitial lung disease, clinical observations, experimental research, Discuss rheumatoid arthritis occur related mechanism of lung damage and kidney disease, Significance in guiding clinical treatment.
2 Methods
2.1 Theoretical Study Use philology, logic analysis ways, Discuss analysis of the connotation of TCM "holism" of the five internal organs, Explore joint Arthralgia and pulmonary paralysis occurred, and to explore the kidney in joint Arthralgia related lung damage.
2.2 Experimental study
2.2.1 We selected 16 female SD rats Randomly, and then causing arthralgia model with Inject of CIA.Observed the pathological changes of the of arthralgia model of lung tissue, calculated the lung coefficient, analysised content of IL-1, IL-6, TNF-alpha and TGF-P of lung tissue.
2.2.2 We selected 64 SD rats randomly, male and female half. Made the arthralgia model, kidney arthralgia model, pseudo-operation group model. Calculated the index of thymus. Analysised content of IL-1, IL-6, TNF-alpha and TGF-βof lung tissue.
3 Result
3.1 The effect of arthralgia pass to lung
3.1.1 Arthralgia model group rats had lung pathological changes. And compared with the physiological group, lung coefficient is higher than the physical group, statistically significant(P<0.05).
3.1.2 Compared with the physiological group, the content of IL-1, IL-6, TNF-alpha, TGF-beta significantly increased in lung, statistically significant(P<0.05).
3.2 The role of renal in pathogenesis
3.2.1 High incidence of female rats than male rats. High incidence of kidney arthralgia than simply arthralgia, sham group.
3.2.2 Whether female or male rats, compared with the physiological group, the thymus index in arthralgia group, kidney arthralgia group, the sham group are lower (P<0.05), with statistical significance. Thymus index was the lowest in kidney arthralgia group.
3.2.3 Whether female or male rats, compared with the physiological group, the content of IL-1, IL-6, TNF-alpha, TGF-beta in arthralgia group, kidney arthralgia group, the sham group are higher (P<0.05), with statistical significance. The content in kidney arthralgia group are highest.
4 Conclusion
4.1 The arthralgia can cause lung tissue damage, IL-1, IL-6, TNF-alpha and TGF-beta in the process of lung injury play an important role.
4.2 Kidney related lung damage occurs to the joint Arthralgia, Kidney dificiency will increase arthralgia, and arthralgia secondary lung injury.
引文
[1]李聪甫校注·中藏经校注·北京：人民卫生出版社,1990：75-76·
[2]黄帝内经素问·北京：人民卫生出版社,1963：353·
[3]张介宾·类经·北京：人民卫生出版社,1965：193,558·
[4]谢观.中华医学大辞典[M].沈阳：辽宁科技出版杜,1994：872.
[5]赵兰才,武维屏.肺间质纤维化的中医研究进展述评.北京中医药大学学报.2000；23(4)24-26
[6]陈金亮,王殿华,张志慧；络病理论与肺纤维化关系探析[J]；中医药学刊；2004；3(4)11-12
[7]金殿春,补阳还五汤加减治疗类风湿肺炎体会.1997；12[8]钟丽丹,洪鸿彬,陈湘君教授治疗风湿病肺间质病变经验介绍.新中医.2006：38(10)13-15
[9]付小芳,刘锡曈等.周平安诊治肺间质纤维化的经验.北京中医药.2010；2(29)99-100
[10]邱新萍.阎小萍教授治疗类风湿性关节炎致间质性肺病临床经验探析.北京中医药.2011；12(10)124-126
[11]李经纬,邓铁涛.中医大辞典[M].北京：人民卫生出版社,1995：951,785,339,1 533.
[12]童学彪.五脏痹实质探讨[J].南京中医药大学学报,1996,12(6)：6-7.
[13]宋建平.肺痹古今论[J].中华医史杂志,1998,28(4)：212-214
[14]姚楚芳,林意菁,蒋树龙.浅谈肺痹与肺间质纤维化[J].中西医结合学报,2004,2(4)：295-296
[15]董振华.从《内经》五脏痹理论探讨风湿病多系统损害的治疗[J].北京中医,2006,25(6)：347-350.
[16]李松伟,王济华.结缔组织病相关肺间质病变的中医探讨.中华中医药杂志.2010；4(25)543-546
[17]王进全,李玺·内经类证论治·西安：陕西科技出版社,1987：242-244
[18]陈燕,吴继全.晁恩祥治疗肺间质纤维化临证思辨特点.世界中医药.2007；3(1)90-92
[19]王勇,马玉琛.痰毒并治类风湿性关节炎致肺间质纤维化.中国中医急症.2009；3(18)395-397
[20]施光其.类风湿肺间质纤维化卫气营血辨证经验.四川中医.2007；25(12)26-27
[21]刘承利.谈治五脏痹[J].新疆中医药,2000,18(3)：58.
[22]王玉光,周平安,刘清泉,等.肺痹证治新诠[是].中国中医基础医学杂志,2002,8(7)：6-7.
[23]宋绍亮,李华.类风湿肺治验.山东中医杂志.2000；10(19)：631
[24]郝伟欣,董振华.升陷汤加味治疗结缔组织病合并肺间质纤维化体会.中华中医药杂志2008；8(23)707-709
[25]陈晓云,苏励等.活血化瘀法治疗类风湿性关节炎并肺间质病变.中华中医药杂志.2010；4(25)629-631
[1]BROWNKK-Rheumatoid lung disease[J]-ProcAm Thorac Soc,2007,4 (5):443-448·
[2]RAJASEKARAN A, SHOVLIN D, SARAVANAN V, et al. Interstitiallung disease in patientswith rheumatoid arthritis:comparison with crypto-genic fibrosing alveolitis over5 years[J]·J Rheumato,l 2006,33 (7):1250-1253·
[3]Zou YQ, LiYS, Ding XN,et al. The clinical significance of HRCT in evaluation of patientswith rheumatoid arthritis-associated interstitial lungdisease:a report from China[J]. Rheumatol Int,2010 Dec 5.
[4]Mohd NoorN, Mohd ShahrirMS, ShahidMS,et al. Clinical and high resolution computed tomography characteristics of patientswith rheumatoidarthritis lung disease[J]. Int JRheum Dis,2009,12(2):136-144.
[5]Gochuico BR, AvilaNA, Chow CK,et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis[J]. Arch InternMed,2008,168(2):159-166.
[6]Brown K K. Rheumatoid lung disease. Proc Am Thorac Soc,2007,4:443-448.
[7]Mohd NoorN, Mohd ShahrirMS, ShahidMS, et al. Clinical and high resolution computed tomography characteristics of patientswith rheumatoid arthritis lung disease[J]. Int JRheum Dis,2009,12(2):136-144.
[8]AFELTRA A, ZENNARO D, GARZIA P, et al·Prevalence of interstitiallung involvement in patients with connective tissue diseases assessed withhigh-resolution computed tomography[J]·Scand J Rheumato,l 2006,35(5):388-394·
[9]American Thoracic, Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of theIdiopathic Interstitial Pneumonias. This joint statement of theAmerican Thoracic Society (ATS), and the EuropeanRespiratory Society (ERS) was adopted by the ATS board ofdirectors, June 2001 and by the ERS Executive Committee,June 2001. Am J Respir Crit Care Med,2002,165:277-304
[10]Nicholson A G, Colby T V, Wells A U. Histopathologicalapproach to patterns of interstitial pneumonia in patient withconnective tissue disorders. Sarcoidosis Vasc Diffuse LungDis,2002,19:10-17.
[11]Leslie K O, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med,2007,28:369-378.
[12]LeeHK, Kim DS, Yoo B,et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associate interstitial lung disease[J]. Chest,2005,127(6):2019-2027.
[13]Song JW, DoKH, KimMY,et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia[J]. Chest,2009,136(1): 23-30.
[14]Turesson C, Matteson EL, ColbyTV, et al. Increased CD4+T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis[J].ArthritisRheum,2005,52(1):73-79.
[15]Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment ofCD20+B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia[J]. ArthritisRheum,2006,54(2):635-641.
[16]Rajasekaran A, Shovlin D, Saravanan V,et al. Interstitial lung disease in patients with rheumatoid arthritis:comparisonwith cryptogenic fibrosingalveolitis over5 years[J]. JRheumato,l 2006,33(7):1250-1253.
[17]Gochuico BR, AvilaNA, Chow CK,et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis[J]. Arch InternMed,2008,168(2):159-166.
[18]Kim EJ, CollardHR, KingTE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance ofhistopathologic and radiographic pattern[J]. Chest,2009,136(5):1397-1405.
[19]SUISSA S, HUDSONM, ERNSTP·Leflunomide use and the risk of inter-stitial lung disease in rheumatoid arthritis·[J]·Arthritis Rheum,2006,54 (5):1435-1439·
[20]SUISSA S, ERNST P, HUDSON M, et al.Newer disease-modifying an-tirheumatic drugs and the risk of serious hepatic adverse events in patientswith rheumatoid arthritis[J]·Am JMed, 2004,117(2):87-92·
[21]KOCHERIL SV, APPLETON B E, SOMERS E C, et al.Comparison ofdisease progression andmortality of connective tissue disease-related inter-stitial lung disease and idiopathic interstitial pneumonia [J]·ArthritisRheum,2005,53 (4):549-557·
[22]KOPI SKIP, SLADEK K, SZCZ'EKLIK J, et al.Expression of insulin-like growth factor-I (IGF-I) in lveolarmacrophages and lymphocytes ob-tained by bronchoalveolar lavage (BAL) in interstitial lung diseases(ILD)·assessmentof IGF-I as a potential localmitogen and antiapoptotic cytokine[J]·FoliaHistochem Cytobio,l 2006,44 (4):249-258·
[23]HAIDER Y, MALIZIAA P, KEATING D T, et al.Hostpredisposition byendogenous transforming growth factor-betaloverexpression promotes pul-monary fibrosis following bleomycin injury[J]·J Inflamm,2007.4:18·
[24]HAYASHI N, YOSHIMOTO T. IZUHARA K, et al.T helper 1 cellsstimulated with ovalbumin and IL-18 induce airway hyperresponsivenessand lung fibrosis by IFN-gamma and IL-13 production[J]·ProcNatlAcadSciUSA,2007,104 (37):4765-14770·
[25]梁柳琴,许韩师,杨岫岩,等·类风湿关节炎血清基质金属蛋白酶-3检测及其临床意义[J]·中山大学学报：医学版,2004,25(B06)：128-131·
[26]BarksbyH E, Lea S R, Preshaw PM, et al. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders [J]. Clin Exp Immuno,l 2007, 149 (2):217-225.
[27]Moynagh P N. The interleukin-1 signalling pathway in astrocytes a key contributor to inflammation in the brain [J]. JAnat,2005,207(3):265-269.
[28]赵桂荣,何冰,李海潮,等.白细胞介素1受体拮抗剂对博莱霉素致大鼠肺纤维化模文献综述一特发性肺间质纤维化的发病机制及治疗研究进展35型的影响[J].北京医科大学学报,1999,31(3)：277.
[29]MosserD M, Zhang X. Interleukin-10:new perspectives on an oldcytokine [J]. Immunol Rev,2008,226:205-218.2.3.3.4IL-18
[30]RKCoker, GLaurent, et al. Localisation of transforming rowth factor beta and beta-mRN Atranscriptsin normal and fibrotic human lung. Thorax,2001,56:549-551
[31]CABRERA S, GAXIOLA M, ARREOLA J L, et al.Overexpression of MMP9 inmacrophages attenuates pulmonary fibrosis induced by bleomycin[J].Int JBiochem CellBio,l 2007,39 (12):2324-2338·
[32]FEGHALI-BOSTWICK C A, TSAIC G, VALENTINEV G, et al.Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis[J].J Immu-no,l 2007,179 (4):2592-2599·
[33]NishimuraK, SugiyamaD, KogataY,et al. Meta-analysis:diagnostic accuracy ofanti-cyclic citrullinated peptide antibody and rheumatoid factor forrheumatoid arthritis[J]. Ann InternMed,2007,146(11):797-808.
[34]Galati S, Beauvillain C, Renier G,et al. Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinatedpeptides antibodies in rheumatoid arthritis[J]. Ann Biol Clin(Paris),2008,66(2):157-164.
[35]Cho SY, Kang SY, Lee HJ,et al. A comparative evaluation of the diagnostic value of anti-cyclic citrullinated peptide and rheumatoid factor inrheumatoid arthritis[J]. Korean JLabMed,2008,28(1):39-45.
[36]LIU R, AHMED KM, NANTAJITD, et al.Therapeutic effects of alpha-lipoic acid on bleomycin-induced pulmonary fibrosis in rats[J]·Int JMolMed,2007,19 (6):865-873·
[37]AYHAN-ARDIC F F, OKENO, YORGANCIOGLU ZR, et al.Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritisand ankylosing spondylitis without respiratory symptoms[J]·Clin Rheuma-to,l 2006,25 (2):213-218·
[38]Rajasekaran A, Shovlin D, Saravanan V,et al. Interstitial lung disease in patients with rheumatoid arthritis:comparisonwith cryptogenic fibrosing alveolitis over 5 years[J]. JRheumato,l 2006,33(7):1250-1253.
[39]Latsi PI, Wells AU,Evaluation and management of alveolitis and interstial lung disease inscleroderoderma[J].Curt Opin Rheumatol,2003,15:748-755.
[40]BIEDERER J, SCHNABEL A, MUHLE C, et al.Correlation betweenHRCT findings, pulmonary function tests and bronchoalveolar lavagecytology in interstitial lung disease associatedwith rheumatoid arthritis[J]·EurRadio,l 2004,14 (2):272-280·
[41]胡清,朱大菊,李雪锋.风湿性疾病合并肺间质病变28例临床分析[J]·新医学,2006,3,(37)：178-180·
[42]]Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis.J Rheumatol,2008,35:1513-1521.
[43]李海去,郑毅.结缔组织病合并间质性肺疾病的的研究进展[J].中华风湿病学杂志,2005,9：438-441.
[44]VassalloR,ThomasCF. Advance sinthetreatment of rheum aticinterstitial lung disease[J] CurrOpinRheumatol,2004,16(3):186-191
[45]Brown KK. Rheumatoid lung disease[J]. ProcAm Thorac Soc,2007,4(5):443-448.
[46]Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease:mycophenolate mofetil as an antifibrotic and disease-modifyingantirheumatic drug[J]. Arch InternMed,2008, 168(15):1718-1719.
[47]Ochi S, Kubota T, Sugihara T,et al. A case report of rheumatoid arthritis complicated with rapidly progressive interstitial pneumonia, multiplebullae and pneumomediastinum, whichwas successfully treated with tacrolimus[J]. Nihon RinshoMenekiGakkaiKaish,i 2008, 31(1):62-67.
[48]MiwaY, IsozakiT, WakabayashiK,et al. Tacrolimus-induced lung injury in a rheumatoid arthritis patientwith interstitial pneumonitis[J]. ModRheumato,l 2008,18(2):208-211.
[49]GOCHUICO B R, AVILANA, CHOW CK, et al.Progressive preclinicalinterstitial lung disease in rheumatoid arthritis [J]·Arch Intern Mel 2008,168 (2):159-166-
[50]ALONSO-RUIZA, PIJOAN J I. ANSUATEGUIE, et al.Tumor necrosisfactor alpha drugs in rheumatoid arthritis:systematic review andmetaanaly-sis of efficacy and safety[J]·BMCMusculoskeletDisord,2008,9 (1):52
[51]FAVALLIEG, MARCHESONIA, COLOMBOG L, et al.Pattern of use,economic burden and vial optimization of infliximab for rheumatoid arthritisin Italy[J]·Clin Exp Rheumato,l 2008,26(1):45-51·
[52]NAKAYAMA S, MUKAE H, SAKAMOTO N, et al.Pirfenidone inhibitsthe expression ofHSP47 in TGF-betal-stimulated human lung fibroblasts[J]·Life Sc,i 2008,82 (3-4): 210-217
[53]吴燕燕.INF-Y在肺损伤纤维化中的研究[J].进展国外医学分 册,2003,30(4)：213-215.
[54]周彩存,刘德纯,王凤超.γ干扰素和吲哚美辛对实验性肺纤维化的影响[J].中华结核和呼吸杂志,1999,22(2)：199.
[55]MOHAMMADI-KARAKANI A, GHAZI-KHANSARI M, SOTOUDEHM.Lisinopril ameliorates paraquat-induced lung fibrosis[J].Clin ChimActa,2006,367 (1-2):170-174·
[56]Matsusaka T,Katori H,Inagami T,et al.Communication between myocytes and MarshallRP,Mc Anulty RJ,Laurent GJ.Angiotens in Ⅱ i smitogenic for human lung fibrosis viaactivation of the type 1 recetor[J].Am J Respir Crit Care Med,2000,16(1):1999-2004.
[1]程士德.内经讲义.素问·痹论,第1版.上海：上海科技出版社,1984：120
[2]赵邵琴.彭建中教授谈辨治类风湿关节炎经验[J].中国中医药报,1994,9(5)：57.
[3]孙素平,米杰.周翠英治疗活动期类风湿关节炎经验[J].山东中医杂志.2004,7(23)：
7.
[4]李稍,杨宝琴,王永炎.新病入络及其证治[J].北京中医药大学学报,2004,27(1)：7-8
[5]董振华.从《内经》五脏痹理论探讨风湿病多系统损害的治疗.北京中医.2006；6(25)347-350.
[6]邱新萍.阎小萍教授治疗类风湿性关节炎致间质性肺病临床经验探析.北京中医药.2011；12(10)124-126
[7]万中人.“肢体痹病”治验[J].开封医专学报,2000,19(1)：52.
[8]王秋梅.浅谈痹病的辨证施护[J].内蒙古中医药,2002,21(3)：45.
[9]张凤娥.痹病的分类命名.中国中医基础医学杂志,2005,11(8)：610.
[10]龚靖渊,叶浩等.类放射性关节炎致间质性肺病的研究进展.湖北中医学院学报.2009：6(11)66-68
[11]BROWNKK·Rheumatoid lung disease [J]. ProcAm Thorac Soc,2007,4 (5):443-448
[12]RAJASEKARAN A, SHOVLIN D, SARAVANAN V, et al. Interstitiallung disease in patientswith rheumatoid arthritis:comparison with crypto-genic fibrosing alveolitis over5 years [J]·J Rheumato,l 2006,33 (7):1250-1253
[13]AFELTRA A,ZENNARO D, GARZIA P, et al.Prevalence of interstitiallung involvement in patients with connective tissue diseases assessed withhigh-resolution computed tomography[J]·Scand J Rheumato,l 2006,35(5): 388-394·
[14]SUISSA S, HUDSONM, ERNSTP. Leflunomide use and the risk of inter-stitial lung disease in rheumatoid arthritis·[J]·Arthritis Rheum,2006,54 (5): 1435-1439
[15]SUISSA S, ERNST P, HUDSON M, et al. Newer disease-modifying an-tirheumatic drugs and the risk of serious hepatic adverse events in patientswith rheumatoid arthritis[J]·Am JMed,2004,117 (2):87-92
[16]KOCHERIL SV, APPLETON B E, SOMERS E C, et al. Comparison ofdisease progression andmortality of connective tissue disease-related inter-stitial lung disease and idiopathic interstitial pneumonia [J]·ArthritisRheum,2005, 53 (4):549-557
[17]KOPI SKIP, SLADEK K, SZCZ' EKLIK J, et al. Expression of insulin-like growth factor-Ⅰ (IGF-Ⅰ) in alveolarmacrophages and lymphocytes ob-tained by bronchoalveolar lavage (BAL) in interstitial lung diseases(ILD)·assessmentof IGF-Ⅰ as a potential localmitogen and antiapoptoticcytokine[J]·FoliaHistochem Cytobio,1 2006,44 (4):249-258
[18]HAIDER Y, MALIZIAA P, KEATING D T, et al.Hostpredisposition by endogenous transforming growth factor-betaloverexpression promotes pul-monary fibrosis following bleomycin injury[J]·J Inflamm,2007,4:18
[19]HAYASHI N, YOSHIMOTO T, IZUHARA K, et al.T helper 1 cellsstimulated with ovalbumin and IL-18 induce airway hyperresponsivenessand lung fibrosis by IFN-gamma and IL-13 production [J]·ProcNatlAcadSciUSA,2007,104 (37): 14765-14770
[20]Marie I, Hachulla E, Ch6rin P, et al.Interstitial lung disease in polymyositis and dermatomyositis[J]. Arthritis Rheum,2002,47:614-622.
[21]Sato H, Lagan AL, Alexopoulou C, et al.The TNF-863A allele strongly associates with ant i centromere antibody posit ivi ty in scleroderma [J]. Arthritis Rheum,2004,50:558-564.
[22]王玉光,周平安,刘清泉.肺痹证治新诠[J].中国中医基础医学杂志,2002,8(7)：6-7
[23]郭强,顾越英,黄文群,等.系统性红斑狼疮患者525例肺部病变的调查[J].中华风湿病学杂志,2004,8：364.
[24]刘正才,尤填义.中医免疫[M].重庆出版杜,1983：15.
[25]蒋明,DAVID YU,林孝义,等.中华风湿病学.北京：华夏出版社,2004：88-105
[26]方素钦,炳辉,叶盈,等.中老年人肾虚证与性激素及免疫功能的研究.福建中医药,2002,33(2)：1-3
[27]李松伟、王济华.结缔组织病相关肺间质病变的中医探讨。中华中医药杂志,2010,4(25)：543-546
[28]盛刚,郭珍,,任月朗.从肺痹论治特发性肺间质纤维化[J].山东中医药大学学报,32(1)：25-26
[29]姚楚芳,林意菁,蒋树龙.浅谈肺痹与肺间质纤维化[J].中西医结合学报,2004,2(4)：295-296
[30]李菊莲,王宇,邓海娟等.肺痹与肺间质纤维化关系探讨[J].甘肃科技,2003,19(12)：113-114.
[31]陈瑞,王鹏.浅谈肺痹与特发性肺纤维化的关系[J].中国中医药信息杂志,2005,12(6)：90-91
[1]戴令娟.老年结缔组织疾病的肺部表现[J].老年医学与保健,2007,4：208.
[2]杨洪军,老年类风湿关节炎并肺间质病变26例临床分析,泰山医学院学报,2008,9(29)：678-680.
[3]张丽芬,类风湿关节炎并发肺间质病变12例临床分析,医学信息,2008,8(21)1435.
[4]万磊,刘健,盛长健,等.活动期类风湿关节炎患者肺功能变化相关性研究,中国中医药信息杂志,2010,(17)：18-22.
[5]赵华,于春艳,早期类风湿关节炎肺功能损害的特点及危险因素分析,医学信息,2010,2(23)：369-370
[6]张奉春.弥漫性结缔组织病与间质性肺疾病的关系[J].中华结核和呼吸杂志,2008,31：243-244.
[7]高惠英,李小峰.结缔组织病所致间质性肺疾病的研究进展[J].国际呼吸杂志,2007,27：673-675.
[8]孔静萍,许桂芳,陈勇,类风湿关节炎患者血清促肾上腺皮质激素皮质醇和白介素-6分泌节律研究,现代实践医学,2008,4(20)：270-272.
[9]庞学丰,高丽珍,吴燕红,等.寒痹康汤对实验性关节炎大鼠血清1L-6 NO的影响,辽宁中医杂志,2009,3(36)：481-482.
[10]苏夏,古松,桂枝附子汤对佐剂性关节炎大鼠IL-6水平影响的实验研究,辽宁中医药大学学报,2011,6(13)：250-251
[11]朱明慧,杨谊,刘旭华,等.类风湿关节炎患者血清白介素-1p、白介素-6、肿瘤死亡因子-α的水平测定及其临床意义,国药论坛杂志,2008,18(29)：9-11
[12]赵志英,马莉莉,姜林娣,肿瘤坏死因子拮抗剂治疗炎性关节炎与患者冬季上呼吸道感染的相关研究,中国临床医学,2010.5(17)：750-752
[13]肖金鱼,王炳胜,王书杰,IL-1及TNF-α在关节炎大鼠模型血清中表达的实验研究,中国中医急症,2011,4(20)：607-608
[14]汤慧华,冯忠军,郭晓华,等.IL-6及TNF-α在类风湿关节炎免疫发病机制中的作用,中华风湿病学杂志,1998,4(2)：237-238
[1]帅世全,刘湘源,黄烽,男性和女性类风湿关节炎对比研究,1998,2(4)：223-225.
[2]裘红梅,李霞,女性类风湿关节炎患者血清中性激素水平的分析,实用全科医学,2007,5(6)：543-544.
[3]刘茜,刘向国,武松.肺气肿肺气虚证模型大鼠脾脏指数、胸腺指数变化的实验研究[J].甘肃中医学院学报,2006,23(1)：20-22.
[1]Zisman DA,Keane MP,BelperioJA,et al.Pulmonary fibrosisMethods Mol Med,2005,117:3-44.
[2]Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet JRare Dis,2008,3:8.
[3]程岚.北京地区类风湿性关节炎的发病与气象要素的相关性研究[D].导师：杨卫彬.：中国中医科学院,2010.
[4]陈瑞,王鹏.浅谈肺痹与特发性肺纤维化的关系[J].中国中医药信息杂志,2005,12(6)：90-91.
[5]盛刚,郭珍,任月朗.从肺痹论治特发性肺间质纤维化[J].山东中医药大学学报,32(1)：25-26
[6]王玉光,周平安,刘清泉.肺痹证治新诠[J].中国中医基础医学杂志,2002,8(7)：6-7
[7]李江,黄茂,武芳,等.川芎嗪对博来霉素致肺纤维化大鼠病理形态学及细胞外基质的干预作用.中华中医药杂志,2007,22(9)：613-615
[2]黄帝内经素问·北京：人民卫生出版社,1963：353·
[3]张介宾·类经·北京：人民卫生出版社,1965：193,558·
[4]谢观.中华医学大辞典[M].沈阳：辽宁科技出版杜,1994：872.
[5]赵兰才,武维屏.肺间质纤维化的中医研究进展述评.北京中医药大学学报.2000；23(4)24-26
[6]陈金亮,王殿华,张志慧；络病理论与肺纤维化关系探析[J]；中医药学刊；2004；3(4)11-12
[7]金殿春,补阳还五汤加减治疗类风湿肺炎体会.1997；12[8]钟丽丹,洪鸿彬,陈湘君教授治疗风湿病肺间质病变经验介绍.新中医.2006：38(10)13-15
[9]付小芳,刘锡曈等.周平安诊治肺间质纤维化的经验.北京中医药.2010；2(29)99-100
[10]邱新萍.阎小萍教授治疗类风湿性关节炎致间质性肺病临床经验探析.北京中医药.2011；12(10)124-126
[11]李经纬,邓铁涛.中医大辞典[M].北京：人民卫生出版社,1995：951,785,339,1 533.
[12]童学彪.五脏痹实质探讨[J].南京中医药大学学报,1996,12(6)：6-7.
[13]宋建平.肺痹古今论[J].中华医史杂志,1998,28(4)：212-214
[14]姚楚芳,林意菁,蒋树龙.浅谈肺痹与肺间质纤维化[J].中西医结合学报,2004,2(4)：295-296
[15]董振华.从《内经》五脏痹理论探讨风湿病多系统损害的治疗[J].北京中医,2006,25(6)：347-350.
[16]李松伟,王济华.结缔组织病相关肺间质病变的中医探讨.中华中医药杂志.2010；4(25)543-546
[17]王进全,李玺·内经类证论治·西安：陕西科技出版社,1987：242-244
[18]陈燕,吴继全.晁恩祥治疗肺间质纤维化临证思辨特点.世界中医药.2007；3(1)90-92
[19]王勇,马玉琛.痰毒并治类风湿性关节炎致肺间质纤维化.中国中医急症.2009；3(18)395-397
[20]施光其.类风湿肺间质纤维化卫气营血辨证经验.四川中医.2007；25(12)26-27
[21]刘承利.谈治五脏痹[J].新疆中医药,2000,18(3)：58.
[22]王玉光,周平安,刘清泉,等.肺痹证治新诠[是].中国中医基础医学杂志,2002,8(7)：6-7.
[23]宋绍亮,李华.类风湿肺治验.山东中医杂志.2000；10(19)：631
[24]郝伟欣,董振华.升陷汤加味治疗结缔组织病合并肺间质纤维化体会.中华中医药杂志2008；8(23)707-709
[25]陈晓云,苏励等.活血化瘀法治疗类风湿性关节炎并肺间质病变.中华中医药杂志.2010；4(25)629-631
[1]BROWNKK-Rheumatoid lung disease[J]-ProcAm Thorac Soc,2007,4 (5):443-448·
[2]RAJASEKARAN A, SHOVLIN D, SARAVANAN V, et al. Interstitiallung disease in patientswith rheumatoid arthritis:comparison with crypto-genic fibrosing alveolitis over5 years[J]·J Rheumato,l 2006,33 (7):1250-1253·
[3]Zou YQ, LiYS, Ding XN,et al. The clinical significance of HRCT in evaluation of patientswith rheumatoid arthritis-associated interstitial lungdisease:a report from China[J]. Rheumatol Int,2010 Dec 5.
[4]Mohd NoorN, Mohd ShahrirMS, ShahidMS,et al. Clinical and high resolution computed tomography characteristics of patientswith rheumatoidarthritis lung disease[J]. Int JRheum Dis,2009,12(2):136-144.
[5]Gochuico BR, AvilaNA, Chow CK,et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis[J]. Arch InternMed,2008,168(2):159-166.
[6]Brown K K. Rheumatoid lung disease. Proc Am Thorac Soc,2007,4:443-448.
[7]Mohd NoorN, Mohd ShahrirMS, ShahidMS, et al. Clinical and high resolution computed tomography characteristics of patientswith rheumatoid arthritis lung disease[J]. Int JRheum Dis,2009,12(2):136-144.
[8]AFELTRA A, ZENNARO D, GARZIA P, et al·Prevalence of interstitiallung involvement in patients with connective tissue diseases assessed withhigh-resolution computed tomography[J]·Scand J Rheumato,l 2006,35(5):388-394·
[9]American Thoracic, Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of theIdiopathic Interstitial Pneumonias. This joint statement of theAmerican Thoracic Society (ATS), and the EuropeanRespiratory Society (ERS) was adopted by the ATS board ofdirectors, June 2001 and by the ERS Executive Committee,June 2001. Am J Respir Crit Care Med,2002,165:277-304
[10]Nicholson A G, Colby T V, Wells A U. Histopathologicalapproach to patterns of interstitial pneumonia in patient withconnective tissue disorders. Sarcoidosis Vasc Diffuse LungDis,2002,19:10-17.
[11]Leslie K O, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med,2007,28:369-378.
[12]LeeHK, Kim DS, Yoo B,et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associate interstitial lung disease[J]. Chest,2005,127(6):2019-2027.
[13]Song JW, DoKH, KimMY,et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia[J]. Chest,2009,136(1): 23-30.
[14]Turesson C, Matteson EL, ColbyTV, et al. Increased CD4+T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis[J].ArthritisRheum,2005,52(1):73-79.
[15]Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment ofCD20+B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia[J]. ArthritisRheum,2006,54(2):635-641.
[16]Rajasekaran A, Shovlin D, Saravanan V,et al. Interstitial lung disease in patients with rheumatoid arthritis:comparisonwith cryptogenic fibrosingalveolitis over5 years[J]. JRheumato,l 2006,33(7):1250-1253.
[17]Gochuico BR, AvilaNA, Chow CK,et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis[J]. Arch InternMed,2008,168(2):159-166.
[18]Kim EJ, CollardHR, KingTE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance ofhistopathologic and radiographic pattern[J]. Chest,2009,136(5):1397-1405.
[19]SUISSA S, HUDSONM, ERNSTP·Leflunomide use and the risk of inter-stitial lung disease in rheumatoid arthritis·[J]·Arthritis Rheum,2006,54 (5):1435-1439·
[20]SUISSA S, ERNST P, HUDSON M, et al.Newer disease-modifying an-tirheumatic drugs and the risk of serious hepatic adverse events in patientswith rheumatoid arthritis[J]·Am JMed, 2004,117(2):87-92·
[21]KOCHERIL SV, APPLETON B E, SOMERS E C, et al.Comparison ofdisease progression andmortality of connective tissue disease-related inter-stitial lung disease and idiopathic interstitial pneumonia [J]·ArthritisRheum,2005,53 (4):549-557·
[22]KOPI SKIP, SLADEK K, SZCZ'EKLIK J, et al.Expression of insulin-like growth factor-I (IGF-I) in lveolarmacrophages and lymphocytes ob-tained by bronchoalveolar lavage (BAL) in interstitial lung diseases(ILD)·assessmentof IGF-I as a potential localmitogen and antiapoptotic cytokine[J]·FoliaHistochem Cytobio,l 2006,44 (4):249-258·
[23]HAIDER Y, MALIZIAA P, KEATING D T, et al.Hostpredisposition byendogenous transforming growth factor-betaloverexpression promotes pul-monary fibrosis following bleomycin injury[J]·J Inflamm,2007.4:18·
[24]HAYASHI N, YOSHIMOTO T. IZUHARA K, et al.T helper 1 cellsstimulated with ovalbumin and IL-18 induce airway hyperresponsivenessand lung fibrosis by IFN-gamma and IL-13 production[J]·ProcNatlAcadSciUSA,2007,104 (37):4765-14770·
[25]梁柳琴,许韩师,杨岫岩,等·类风湿关节炎血清基质金属蛋白酶-3检测及其临床意义[J]·中山大学学报：医学版,2004,25(B06)：128-131·
[26]BarksbyH E, Lea S R, Preshaw PM, et al. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders [J]. Clin Exp Immuno,l 2007, 149 (2):217-225.
[27]Moynagh P N. The interleukin-1 signalling pathway in astrocytes a key contributor to inflammation in the brain [J]. JAnat,2005,207(3):265-269.
[28]赵桂荣,何冰,李海潮,等.白细胞介素1受体拮抗剂对博莱霉素致大鼠肺纤维化模文献综述一特发性肺间质纤维化的发病机制及治疗研究进展35型的影响[J].北京医科大学学报,1999,31(3)：277.
[29]MosserD M, Zhang X. Interleukin-10:new perspectives on an oldcytokine [J]. Immunol Rev,2008,226:205-218.2.3.3.4IL-18
[30]RKCoker, GLaurent, et al. Localisation of transforming rowth factor beta and beta-mRN Atranscriptsin normal and fibrotic human lung. Thorax,2001,56:549-551
[31]CABRERA S, GAXIOLA M, ARREOLA J L, et al.Overexpression of MMP9 inmacrophages attenuates pulmonary fibrosis induced by bleomycin[J].Int JBiochem CellBio,l 2007,39 (12):2324-2338·
[32]FEGHALI-BOSTWICK C A, TSAIC G, VALENTINEV G, et al.Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis[J].J Immu-no,l 2007,179 (4):2592-2599·
[33]NishimuraK, SugiyamaD, KogataY,et al. Meta-analysis:diagnostic accuracy ofanti-cyclic citrullinated peptide antibody and rheumatoid factor forrheumatoid arthritis[J]. Ann InternMed,2007,146(11):797-808.
[34]Galati S, Beauvillain C, Renier G,et al. Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinatedpeptides antibodies in rheumatoid arthritis[J]. Ann Biol Clin(Paris),2008,66(2):157-164.
[35]Cho SY, Kang SY, Lee HJ,et al. A comparative evaluation of the diagnostic value of anti-cyclic citrullinated peptide and rheumatoid factor inrheumatoid arthritis[J]. Korean JLabMed,2008,28(1):39-45.
[36]LIU R, AHMED KM, NANTAJITD, et al.Therapeutic effects of alpha-lipoic acid on bleomycin-induced pulmonary fibrosis in rats[J]·Int JMolMed,2007,19 (6):865-873·
[37]AYHAN-ARDIC F F, OKENO, YORGANCIOGLU ZR, et al.Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritisand ankylosing spondylitis without respiratory symptoms[J]·Clin Rheuma-to,l 2006,25 (2):213-218·
[38]Rajasekaran A, Shovlin D, Saravanan V,et al. Interstitial lung disease in patients with rheumatoid arthritis:comparisonwith cryptogenic fibrosing alveolitis over 5 years[J]. JRheumato,l 2006,33(7):1250-1253.
[39]Latsi PI, Wells AU,Evaluation and management of alveolitis and interstial lung disease inscleroderoderma[J].Curt Opin Rheumatol,2003,15:748-755.
[40]BIEDERER J, SCHNABEL A, MUHLE C, et al.Correlation betweenHRCT findings, pulmonary function tests and bronchoalveolar lavagecytology in interstitial lung disease associatedwith rheumatoid arthritis[J]·EurRadio,l 2004,14 (2):272-280·
[41]胡清,朱大菊,李雪锋.风湿性疾病合并肺间质病变28例临床分析[J]·新医学,2006,3,(37)：178-180·
[42]]Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis.J Rheumatol,2008,35:1513-1521.
[43]李海去,郑毅.结缔组织病合并间质性肺疾病的的研究进展[J].中华风湿病学杂志,2005,9：438-441.
[44]VassalloR,ThomasCF. Advance sinthetreatment of rheum aticinterstitial lung disease[J] CurrOpinRheumatol,2004,16(3):186-191
[45]Brown KK. Rheumatoid lung disease[J]. ProcAm Thorac Soc,2007,4(5):443-448.
[46]Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease:mycophenolate mofetil as an antifibrotic and disease-modifyingantirheumatic drug[J]. Arch InternMed,2008, 168(15):1718-1719.
[47]Ochi S, Kubota T, Sugihara T,et al. A case report of rheumatoid arthritis complicated with rapidly progressive interstitial pneumonia, multiplebullae and pneumomediastinum, whichwas successfully treated with tacrolimus[J]. Nihon RinshoMenekiGakkaiKaish,i 2008, 31(1):62-67.
[48]MiwaY, IsozakiT, WakabayashiK,et al. Tacrolimus-induced lung injury in a rheumatoid arthritis patientwith interstitial pneumonitis[J]. ModRheumato,l 2008,18(2):208-211.
[49]GOCHUICO B R, AVILANA, CHOW CK, et al.Progressive preclinicalinterstitial lung disease in rheumatoid arthritis [J]·Arch Intern Mel 2008,168 (2):159-166-
[50]ALONSO-RUIZA, PIJOAN J I. ANSUATEGUIE, et al.Tumor necrosisfactor alpha drugs in rheumatoid arthritis:systematic review andmetaanaly-sis of efficacy and safety[J]·BMCMusculoskeletDisord,2008,9 (1):52
[51]FAVALLIEG, MARCHESONIA, COLOMBOG L, et al.Pattern of use,economic burden and vial optimization of infliximab for rheumatoid arthritisin Italy[J]·Clin Exp Rheumato,l 2008,26(1):45-51·
[52]NAKAYAMA S, MUKAE H, SAKAMOTO N, et al.Pirfenidone inhibitsthe expression ofHSP47 in TGF-betal-stimulated human lung fibroblasts[J]·Life Sc,i 2008,82 (3-4): 210-217
[53]吴燕燕.INF-Y在肺损伤纤维化中的研究[J].进展国外医学分 册,2003,30(4)：213-215.
[54]周彩存,刘德纯,王凤超.γ干扰素和吲哚美辛对实验性肺纤维化的影响[J].中华结核和呼吸杂志,1999,22(2)：199.
[55]MOHAMMADI-KARAKANI A, GHAZI-KHANSARI M, SOTOUDEHM.Lisinopril ameliorates paraquat-induced lung fibrosis[J].Clin ChimActa,2006,367 (1-2):170-174·
[56]Matsusaka T,Katori H,Inagami T,et al.Communication between myocytes and MarshallRP,Mc Anulty RJ,Laurent GJ.Angiotens in Ⅱ i smitogenic for human lung fibrosis viaactivation of the type 1 recetor[J].Am J Respir Crit Care Med,2000,16(1):1999-2004.
[1]程士德.内经讲义.素问·痹论,第1版.上海：上海科技出版社,1984：120
[2]赵邵琴.彭建中教授谈辨治类风湿关节炎经验[J].中国中医药报,1994,9(5)：57.
[3]孙素平,米杰.周翠英治疗活动期类风湿关节炎经验[J].山东中医杂志.2004,7(23)：
7.
[4]李稍,杨宝琴,王永炎.新病入络及其证治[J].北京中医药大学学报,2004,27(1)：7-8
[5]董振华.从《内经》五脏痹理论探讨风湿病多系统损害的治疗.北京中医.2006；6(25)347-350.
[6]邱新萍.阎小萍教授治疗类风湿性关节炎致间质性肺病临床经验探析.北京中医药.2011；12(10)124-126
[7]万中人.“肢体痹病”治验[J].开封医专学报,2000,19(1)：52.
[8]王秋梅.浅谈痹病的辨证施护[J].内蒙古中医药,2002,21(3)：45.
[9]张凤娥.痹病的分类命名.中国中医基础医学杂志,2005,11(8)：610.
[10]龚靖渊,叶浩等.类放射性关节炎致间质性肺病的研究进展.湖北中医学院学报.2009：6(11)66-68
[11]BROWNKK·Rheumatoid lung disease [J]. ProcAm Thorac Soc,2007,4 (5):443-448
[12]RAJASEKARAN A, SHOVLIN D, SARAVANAN V, et al. Interstitiallung disease in patientswith rheumatoid arthritis:comparison with crypto-genic fibrosing alveolitis over5 years [J]·J Rheumato,l 2006,33 (7):1250-1253
[13]AFELTRA A,ZENNARO D, GARZIA P, et al.Prevalence of interstitiallung involvement in patients with connective tissue diseases assessed withhigh-resolution computed tomography[J]·Scand J Rheumato,l 2006,35(5): 388-394·
[14]SUISSA S, HUDSONM, ERNSTP. Leflunomide use and the risk of inter-stitial lung disease in rheumatoid arthritis·[J]·Arthritis Rheum,2006,54 (5): 1435-1439
[15]SUISSA S, ERNST P, HUDSON M, et al. Newer disease-modifying an-tirheumatic drugs and the risk of serious hepatic adverse events in patientswith rheumatoid arthritis[J]·Am JMed,2004,117 (2):87-92
[16]KOCHERIL SV, APPLETON B E, SOMERS E C, et al. Comparison ofdisease progression andmortality of connective tissue disease-related inter-stitial lung disease and idiopathic interstitial pneumonia [J]·ArthritisRheum,2005, 53 (4):549-557
[17]KOPI SKIP, SLADEK K, SZCZ' EKLIK J, et al. Expression of insulin-like growth factor-Ⅰ (IGF-Ⅰ) in alveolarmacrophages and lymphocytes ob-tained by bronchoalveolar lavage (BAL) in interstitial lung diseases(ILD)·assessmentof IGF-Ⅰ as a potential localmitogen and antiapoptoticcytokine[J]·FoliaHistochem Cytobio,1 2006,44 (4):249-258
[18]HAIDER Y, MALIZIAA P, KEATING D T, et al.Hostpredisposition by endogenous transforming growth factor-betaloverexpression promotes pul-monary fibrosis following bleomycin injury[J]·J Inflamm,2007,4:18
[19]HAYASHI N, YOSHIMOTO T, IZUHARA K, et al.T helper 1 cellsstimulated with ovalbumin and IL-18 induce airway hyperresponsivenessand lung fibrosis by IFN-gamma and IL-13 production [J]·ProcNatlAcadSciUSA,2007,104 (37): 14765-14770
[20]Marie I, Hachulla E, Ch6rin P, et al.Interstitial lung disease in polymyositis and dermatomyositis[J]. Arthritis Rheum,2002,47:614-622.
[21]Sato H, Lagan AL, Alexopoulou C, et al.The TNF-863A allele strongly associates with ant i centromere antibody posit ivi ty in scleroderma [J]. Arthritis Rheum,2004,50:558-564.
[22]王玉光,周平安,刘清泉.肺痹证治新诠[J].中国中医基础医学杂志,2002,8(7)：6-7
[23]郭强,顾越英,黄文群,等.系统性红斑狼疮患者525例肺部病变的调查[J].中华风湿病学杂志,2004,8：364.
[24]刘正才,尤填义.中医免疫[M].重庆出版杜,1983：15.
[25]蒋明,DAVID YU,林孝义,等.中华风湿病学.北京：华夏出版社,2004：88-105
[26]方素钦,炳辉,叶盈,等.中老年人肾虚证与性激素及免疫功能的研究.福建中医药,2002,33(2)：1-3
[27]李松伟、王济华.结缔组织病相关肺间质病变的中医探讨。中华中医药杂志,2010,4(25)：543-546
[28]盛刚,郭珍,,任月朗.从肺痹论治特发性肺间质纤维化[J].山东中医药大学学报,32(1)：25-26
[29]姚楚芳,林意菁,蒋树龙.浅谈肺痹与肺间质纤维化[J].中西医结合学报,2004,2(4)：295-296
[30]李菊莲,王宇,邓海娟等.肺痹与肺间质纤维化关系探讨[J].甘肃科技,2003,19(12)：113-114.
[31]陈瑞,王鹏.浅谈肺痹与特发性肺纤维化的关系[J].中国中医药信息杂志,2005,12(6)：90-91
[1]戴令娟.老年结缔组织疾病的肺部表现[J].老年医学与保健,2007,4：208.
[2]杨洪军,老年类风湿关节炎并肺间质病变26例临床分析,泰山医学院学报,2008,9(29)：678-680.
[3]张丽芬,类风湿关节炎并发肺间质病变12例临床分析,医学信息,2008,8(21)1435.
[4]万磊,刘健,盛长健,等.活动期类风湿关节炎患者肺功能变化相关性研究,中国中医药信息杂志,2010,(17)：18-22.
[5]赵华,于春艳,早期类风湿关节炎肺功能损害的特点及危险因素分析,医学信息,2010,2(23)：369-370
[6]张奉春.弥漫性结缔组织病与间质性肺疾病的关系[J].中华结核和呼吸杂志,2008,31：243-244.
[7]高惠英,李小峰.结缔组织病所致间质性肺疾病的研究进展[J].国际呼吸杂志,2007,27：673-675.
[8]孔静萍,许桂芳,陈勇,类风湿关节炎患者血清促肾上腺皮质激素皮质醇和白介素-6分泌节律研究,现代实践医学,2008,4(20)：270-272.
[9]庞学丰,高丽珍,吴燕红,等.寒痹康汤对实验性关节炎大鼠血清1L-6 NO的影响,辽宁中医杂志,2009,3(36)：481-482.
[10]苏夏,古松,桂枝附子汤对佐剂性关节炎大鼠IL-6水平影响的实验研究,辽宁中医药大学学报,2011,6(13)：250-251
[11]朱明慧,杨谊,刘旭华,等.类风湿关节炎患者血清白介素-1p、白介素-6、肿瘤死亡因子-α的水平测定及其临床意义,国药论坛杂志,2008,18(29)：9-11
[12]赵志英,马莉莉,姜林娣,肿瘤坏死因子拮抗剂治疗炎性关节炎与患者冬季上呼吸道感染的相关研究,中国临床医学,2010.5(17)：750-752
[13]肖金鱼,王炳胜,王书杰,IL-1及TNF-α在关节炎大鼠模型血清中表达的实验研究,中国中医急症,2011,4(20)：607-608
[14]汤慧华,冯忠军,郭晓华,等.IL-6及TNF-α在类风湿关节炎免疫发病机制中的作用,中华风湿病学杂志,1998,4(2)：237-238
[1]帅世全,刘湘源,黄烽,男性和女性类风湿关节炎对比研究,1998,2(4)：223-225.
[2]裘红梅,李霞,女性类风湿关节炎患者血清中性激素水平的分析,实用全科医学,2007,5(6)：543-544.
[3]刘茜,刘向国,武松.肺气肿肺气虚证模型大鼠脾脏指数、胸腺指数变化的实验研究[J].甘肃中医学院学报,2006,23(1)：20-22.
[1]Zisman DA,Keane MP,BelperioJA,et al.Pulmonary fibrosisMethods Mol Med,2005,117:3-44.
[2]Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet JRare Dis,2008,3:8.
[3]程岚.北京地区类风湿性关节炎的发病与气象要素的相关性研究[D].导师：杨卫彬.：中国中医科学院,2010.
[4]陈瑞,王鹏.浅谈肺痹与特发性肺纤维化的关系[J].中国中医药信息杂志,2005,12(6)：90-91.
[5]盛刚,郭珍,任月朗.从肺痹论治特发性肺间质纤维化[J].山东中医药大学学报,32(1)：25-26
[6]王玉光,周平安,刘清泉.肺痹证治新诠[J].中国中医基础医学杂志,2002,8(7)：6-7
[7]李江,黄茂,武芳,等.川芎嗪对博来霉素致肺纤维化大鼠病理形态学及细胞外基质的干预作用.中华中医药杂志,2007,22(9)：613-615
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |